NXTM 16.46 Nxstage Medical $NXTM Hit a 52 week hig
Post# of 23
Posted On: 11/07/2014 12:01:20 AM
NXTM 16.46 Nxstage Medical $NXTM Hit a 52 week high of 17.25 Closing the day 11/06/14 at 16.46 +1.26 +8.29% With a day low of 16.01 and a total volume of 2,657,180.
NXTM Recent Posts: http://investorshangout.com/NxStage-Medical-Inc-NXTM-54950/
NXTM Nxstage Medical Recent Headline News
Why NxStage Medical Inc. Stock Surged Higher
Sean Williams, The Motley Fool - Motley Fool - Thu Nov 06, 12:20PM CST
This article originally appeared as part of ongoing coverage in our premium Motley Fool Rule Breakers service... we hope you enjoy this complimentary peek! What's happening: Shares of NxStage Medical , a developer of medical devices used...
NXTM: 16.46 (+1.26)
NxStage Reports Record Third Quarter 2014 Financial Results And Raises Full-Year Revenue Guidance
PR Newswire - Thu Nov 06, 6:31AM CST
NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today reported third quarter revenue that exceeds the top end of its guidance range.
NXTM: 16.46 (+1.26)
NxStage Announces Winner of First Annual Nurse Hero Campaign
PR Newswire - Tue Nov 04, 3:01PM CST
NxStage® Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced Nancy Lisak, RN, as the winner of its Nurse Hero Campaign. Lisak received over 4,000 votes from patients, care partners and colleagues to top 41 other Nurse Hero nominees. The campaign is a first-of-its-kind home hemodialysis (HHD) nurse recognition that honors the important role these nurses play in helping patients to receive potentially life-changing dialysis therapy. NxStage and Lisak's employer, Affiliated Dialysis Center (ADC), will recognize Lisak at a special ceremony on November 5, 2014 at ADC's corporate headquarters in Glen Ellyn, Illinois.
NXTM: 16.46 (+1.26)
Grand Opening of NxStage Kidney Care Oak Brook IL Center
PR Newswire - Thu Oct 30, 7:00AM CDT
NxStage® Kidney Care, Inc., a subsidiary of NxStage® Medical, Inc. (Nasdaq: NXTM), is proud to host the grand opening ceremony of its Oak Brook, Illinois center at 1600 W. 16th Street on November 20, 2014 from 3pm - 7pm. The Oak Brook center is operated by highly trained medical staff who are committed to providing patients with enhanced access to the significant clinical and quality of life benefits made possible through more flexible dialysis treatment options.
NXTM: 16.46 (+1.26)
NxStage Director of Public Policy Honored for Dedication to Patient Advocacy
PR Newswire - Fri Oct 24, 7:00AM CDT
NxStage® Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, is proud to announce that Linda Upchurch, Director of Public Policy at NxStage, has been named the recipient of Home Dialyzors United's inaugural Richard J. Berkowitz Memorial Award in memory of the organization's founder. Home Dialyzors United (HDU) is a non-profit organization grounded in raising awareness of the clinical and lifestyle benefits of home dialysis treatment for kidney failure patients. HDU established this award to recognize an individual who embodies Berkowitz's legacy by showing tremendous commitment to patient education and advocacy.
NXTM: 16.46 (+1.26)
NxStage Kidney Care Hosts Grand Opening Event at Florida Dialysis Center
PR Newswire - Wed Oct 08, 8:57AM CDT
NxStage® Kidney Care, Inc., a subsidiary of NxStage Medical, Inc. (Nasdaq: NXTM), today announced the grand opening of the company's South Orlando, Florida dialysis center. The new state-of-the art facility, located at 14522 Landstar Boulevard, is owned and managed in partnership with Central Florida Kidney Center, a nationally recognized dialysis provider for over 42 years. To celebrate, the center will host a ribbon cutting ceremony on November 7, 2014 from 3pm to 7pm with special guest recording artist and former NxStage System One(TM) patient David RUSH.
NXTM: 16.46 (+1.26)
NxStage® to Report Third Quarter 2014 Financial Results
PR Newswire - Tue Oct 07, 7:00AM CDT
NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced plans to release its financial results for the third quarter ended September 30, 2014, on Thursday, November 6, 2014, before the opening of the financial markets.
NXTM: 16.46 (+1.26)
PXR, CEW, EMQ, NXTM, BWP, RYU Are Seasonally Ripe To Go Up In the Next Five Weeks
M2 - Mon Sep 22, 3:57AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Prominex Resource Corp (NYSE
XR), Claymore Investments Inc (NYSE:CEW), Entergy Mississippi Inc. 6% Series First Mortgage Bonds due November 1 2032 (NYSE:EMQ), NxStage Medical Inc (NASDAQ:NXTM), Boardwalk Pipeline Partners LP (NYSE:BWP), Guggenheim Invest S&P 500 Eql Wght Utilities ETF (NYSE:RYU) and each have a high seasonal probability to go Up in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
NXTM: 16.46 (+1.26), PXR: 37.11 (+0.03), BWP: 16.69 (+0.04), EMQ: 25.55 (+0.05), RYU: 76.52 (-1.68), CEW: 19.38 (-0.15)
NxStage passes US FDA clearance of single needle technology OneSite
M2 - Wed Sep 17, 6:52AM CDT
Dialysis products company NxStage Medical (NasdaqGS:NXTM) reported on Tuesday the receipt of US Food & Drug Administration's clearance for its single needle technology, OneSite.
NXTM: 16.46 (+1.26)
NxStage Announces FDA Clearance of Single Needle Technology
PR Newswire - Tue Sep 16, 7:00AM CDT
NxStage® Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced its single needle technology, OneSite(TM), has received FDA clearance.
NXTM: 16.46 (+1.26)
Global Dialysis Products and Services (Hemodialysis Products, Peritoneal Dialysis Products
M2 - Thu Sep 11, 5:50AM CDT
Research and Markets (http://www.researchandmarkets.com/research/c8vw2r/dialysis_products) has announced the addition of the "Dialysis Products and Services Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020" report to their offering. According to the National Institutes of Health, the worldwide number of patients with chronic kidney disease is rising rapidly and is expected to rise by approximately 5% to 8% annually. Increasing prevalence of diabetes and hypertension are the two primary causes of end stage renal disease in major developing countries like China, Brazil and India and is also contributing to the growth of overall dialysis products and services market. According to the American Kidney Fund, diabetes and hypertension are responsible for 38.4% and 25% of all cases of kidney failures, respectively. Similarly, increasing geriatric population and low preference by patients above 65 years of age to opt for kidney transplant is also driving the growth of dialysis products and services market. According to the Australian Institute of Health and Welfare, the proportion of people opting for kidney transplantation decreases with age. Moreover, increasing awareness about peritoneal dialysis is expected to boost the growth of the market in the near future. The global dialysis products and services market is segmented by type of procedures and type of services. The procedures market is further segmented into hemodialysis and peritoneal dialysis. Further, the hemodialysis segment (HD) is classified into HD machine, dialyzer, access products/catheters, bloodlines, concentrates and others, which include water treatment systems and fistula needles. Hemodialysis, being the oldest and most preferred technique for dialysis procedure, Hemodialysis machines captures the largest share, of the total market in 2013. The segment is expected to lead the market during the forecast period from 2014 to 2020. Similarly, peritoneal dialysis (PD) segment is classified into concentrates/dialysate, PD machines, catheters, and transfer sets. Among these, the PD concentrates/dialysate segment is accounted for largest market share in 2013 and is expected to grow at an attractive higher growth rate during the forecast period from 2014 to 2020. The major factors responsible for the significant growth of this segment are increase in the number of patients preferring peritoneal dialysis, and rising demand of patients to be dialyzed overnight with the aid of peritoneal dialysis. Dialysis Products and Services Market, by Product type: Hemodialysis - HD Machines - Dialyzers - HD Access Products/Catheters - Bloodlines - HD Concentrates/Dialysate - Others (Water Treatment System, Fistula Needles) Peritoneal Dialysis - Concentrates/Dialysate - PD Machines - PD Catheters - PD Transfer Sets Dialysis Products and Services Market, by Type of Services: - In-center Dialysis - Home Dialysis Companies Mentioned - Asahi Kasei Corporation - B. Braun Melsungen AG - Baxter International, Inc. - C. R. Bard, Inc. - Cantel Medical Corporation - Covidien plc - DaVita Healthcare Partners, Inc. - Fresenius SE & Co. KGaA - Kawasumi Laboratories, Inc. - Medical Components, Inc. - Nikkiso Co., Ltd. - Nipro Corporation - NxStage Medical, Inc. - Rockwell Medical Technologies, Inc. For more information visit http://www.researchandmarkets.com/research/c8...s_products
NXTM: 16.46 (+1.26), BAX: 71.60 (+0.70), RMTI: 9.33 (+0.15), CMN: 41.50 (+0.02)
NxStage Patients Participate in 257-Mile Tour DaVita Bike Ride
PR Newswire - Wed Sep 10, 7:00AM CDT
NxStage Medical, Inc. (NASDAQ: NXTM), a leading manufacturer of innovative dialysis products, is proud to support four kidney failure patients performing home hemodialysis (HHD) treatment with the NxStage® System One(TM) as they ride in the eighth annual Tour DaVita®. Beginning on September 14 in Oregon, each patient will bike up to 257 miles over the course of three days, raising awareness for kidney disease and dialysis treatment options, including HHD. Thanks to the portability and flexibility of treatment schedules with the NxStage System One, all four patients will dialyze in a recreational vehicle along the route with the support of a care partner.
NXTM: 16.46 (+1.26)
NxStage Kidney Care Opens New Orlando Florida Dialysis Center
PR Newswire - Wed Aug 20, 9:00AM CDT
NxStage Kidney Care, Inc., a subsidiary of NxStage Medical, Inc. (Nasdaq: NXTM), today announced the opening of a new dialysis center serving the south Orlando area. NxStage Kidney Care's staff of highly trained nurses and medical professionals are committed to providing enhanced access to the significant clinical and quality of life benefits made possible through home therapy as well as flexible in-center options at the frequency and duration that works best for the patient.
NXTM: 16.46 (+1.26)
NxStage Medical appoints Dr. Allan J. Collins as senior medical advisor
M2 - Tue Aug 12, 7:27AM CDT
Medical dialysis company NxStage Medical (Nasdaq GS:NXTM) disclosed on Tuesday that Allan J Collins MD, has been elected as its senior medical advisor and head of its medical advisory board.
NXTM: 16.46 (+1.26)
Allan J. Collins, M.D., to join NxStage as Senior Medical Advisor
PR Newswire - Tue Aug 12, 7:00AM CDT
NxStage Medical, Inc. (NASDAQ: NXTM), a leading manufacturer of innovative dialysis products, announced today that Allan J. Collins, M.D., a recognized worldwide leader in the field of nephrology, will join the Company as Senior Medical Advisor and head the Company's Medical Advisory Board.
NXTM: 16.46 (+1.26)
NxStage Reports Record Second Quarter 2014 Financial Results And Increases Full-Year Revenue Guidance
PR Newswire - Thu Aug 07, 6:38AM CDT
NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today reported second quarter revenue that exceeds the top end of its guidance range.
NXTM: 16.46 (+1.26)
NxStage to Present at the 34th Annual Canaccord Genuity Growth Conference
PR Newswire - Fri Aug 01, 7:00AM CDT
NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced that Jeffrey H. Burbank, Chief Executive Officer, and Mathew Towse, Chief Financial Officer, will present at the 34th Annual Canaccord Genuity Growth Conference being held at the InterContinental in Boston, MA, on Wednesday, August 13th at 4:30 p.m. ET. A webcast of the event will be made available at http://ir.nxstage.com/.
NXTM: 16.46 (+1.26)
NxStage® to Report Second Quarter 2014 Financial Results
PR Newswire - Thu Jul 17, 7:01AM CDT
NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced plans to release its financial results for the second quarter ended June 30, 2014, on Thursday, August 7, 2014, before the opening of the financial markets.
NXTM: 16.46 (+1.26)
NxStage Drives to Educate Kidney Patients
PR Newswire - Wed Jul 16, 9:09AM CDT
NxStage® Medical, Inc. (NASDAQ: NXTM), a leading manufacturer of innovative dialysis products, announced today the launch of the NxStage Freedom Tour, a two week road trip in a recreational vehicle to promote and educate dialysis patients on the benefits of home hemodialysis with the NxStage System One(TM). Traveling in the NxStage Freedom Coach are NxStage field marketing specialists Charissa Rice and Harvey Wells. During the nine city tour, the duo will make stops outside of dialysis centers in Maryland, Pennsylvania, Connecticut, Massachusetts, New Jersey, New York, Virginia and North Carolina. Patients and care partners are invited inside the NxStage Freedom coach to watch Rice, who is also a NxStage user, perform her treatments with her care partner, learn about home hemodialysis and hear first-hand how the therapy has helped both Rice and Wells to reclaim their lives.
NXTM: 16.46 (+1.26)
Mariel Therapeutics Acquires Stryker Assets - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jul 08, 5:35PM CDT
Stryker Corporation's (SYK) BMP-7 assets will be used by Mariel for the potential treatment of osteoarthritis, chronic kidney disease and other organ fibrosis conditions.
NXTM: 16.46 (+1.26), CSII: 29.87 (-0.01), OSUR: 9.01 (+0.32), SYK: 88.55 (+0.53)
NXTM Recent Posts: http://investorshangout.com/NxStage-Medical-Inc-NXTM-54950/
NXTM Nxstage Medical Recent Headline News
Why NxStage Medical Inc. Stock Surged Higher
Sean Williams, The Motley Fool - Motley Fool - Thu Nov 06, 12:20PM CST
This article originally appeared as part of ongoing coverage in our premium Motley Fool Rule Breakers service... we hope you enjoy this complimentary peek! What's happening: Shares of NxStage Medical , a developer of medical devices used...
NXTM: 16.46 (+1.26)
NxStage Reports Record Third Quarter 2014 Financial Results And Raises Full-Year Revenue Guidance
PR Newswire - Thu Nov 06, 6:31AM CST
NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today reported third quarter revenue that exceeds the top end of its guidance range.
NXTM: 16.46 (+1.26)
NxStage Announces Winner of First Annual Nurse Hero Campaign
PR Newswire - Tue Nov 04, 3:01PM CST
NxStage® Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced Nancy Lisak, RN, as the winner of its Nurse Hero Campaign. Lisak received over 4,000 votes from patients, care partners and colleagues to top 41 other Nurse Hero nominees. The campaign is a first-of-its-kind home hemodialysis (HHD) nurse recognition that honors the important role these nurses play in helping patients to receive potentially life-changing dialysis therapy. NxStage and Lisak's employer, Affiliated Dialysis Center (ADC), will recognize Lisak at a special ceremony on November 5, 2014 at ADC's corporate headquarters in Glen Ellyn, Illinois.
NXTM: 16.46 (+1.26)
Grand Opening of NxStage Kidney Care Oak Brook IL Center
PR Newswire - Thu Oct 30, 7:00AM CDT
NxStage® Kidney Care, Inc., a subsidiary of NxStage® Medical, Inc. (Nasdaq: NXTM), is proud to host the grand opening ceremony of its Oak Brook, Illinois center at 1600 W. 16th Street on November 20, 2014 from 3pm - 7pm. The Oak Brook center is operated by highly trained medical staff who are committed to providing patients with enhanced access to the significant clinical and quality of life benefits made possible through more flexible dialysis treatment options.
NXTM: 16.46 (+1.26)
NxStage Director of Public Policy Honored for Dedication to Patient Advocacy
PR Newswire - Fri Oct 24, 7:00AM CDT
NxStage® Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, is proud to announce that Linda Upchurch, Director of Public Policy at NxStage, has been named the recipient of Home Dialyzors United's inaugural Richard J. Berkowitz Memorial Award in memory of the organization's founder. Home Dialyzors United (HDU) is a non-profit organization grounded in raising awareness of the clinical and lifestyle benefits of home dialysis treatment for kidney failure patients. HDU established this award to recognize an individual who embodies Berkowitz's legacy by showing tremendous commitment to patient education and advocacy.
NXTM: 16.46 (+1.26)
NxStage Kidney Care Hosts Grand Opening Event at Florida Dialysis Center
PR Newswire - Wed Oct 08, 8:57AM CDT
NxStage® Kidney Care, Inc., a subsidiary of NxStage Medical, Inc. (Nasdaq: NXTM), today announced the grand opening of the company's South Orlando, Florida dialysis center. The new state-of-the art facility, located at 14522 Landstar Boulevard, is owned and managed in partnership with Central Florida Kidney Center, a nationally recognized dialysis provider for over 42 years. To celebrate, the center will host a ribbon cutting ceremony on November 7, 2014 from 3pm to 7pm with special guest recording artist and former NxStage System One(TM) patient David RUSH.
NXTM: 16.46 (+1.26)
NxStage® to Report Third Quarter 2014 Financial Results
PR Newswire - Tue Oct 07, 7:00AM CDT
NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced plans to release its financial results for the third quarter ended September 30, 2014, on Thursday, November 6, 2014, before the opening of the financial markets.
NXTM: 16.46 (+1.26)
PXR, CEW, EMQ, NXTM, BWP, RYU Are Seasonally Ripe To Go Up In the Next Five Weeks
M2 - Mon Sep 22, 3:57AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Prominex Resource Corp (NYSE
XR), Claymore Investments Inc (NYSE:CEW), Entergy Mississippi Inc. 6% Series First Mortgage Bonds due November 1 2032 (NYSE:EMQ), NxStage Medical Inc (NASDAQ:NXTM), Boardwalk Pipeline Partners LP (NYSE:BWP), Guggenheim Invest S&P 500 Eql Wght Utilities ETF (NYSE:RYU) and each have a high seasonal probability to go Up in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at: NXTM: 16.46 (+1.26), PXR: 37.11 (+0.03), BWP: 16.69 (+0.04), EMQ: 25.55 (+0.05), RYU: 76.52 (-1.68), CEW: 19.38 (-0.15)
NxStage passes US FDA clearance of single needle technology OneSite
M2 - Wed Sep 17, 6:52AM CDT
Dialysis products company NxStage Medical (NasdaqGS:NXTM) reported on Tuesday the receipt of US Food & Drug Administration's clearance for its single needle technology, OneSite.
NXTM: 16.46 (+1.26)
NxStage Announces FDA Clearance of Single Needle Technology
PR Newswire - Tue Sep 16, 7:00AM CDT
NxStage® Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced its single needle technology, OneSite(TM), has received FDA clearance.
NXTM: 16.46 (+1.26)
Global Dialysis Products and Services (Hemodialysis Products, Peritoneal Dialysis Products
M2 - Thu Sep 11, 5:50AM CDT
Research and Markets (http://www.researchandmarkets.com/research/c8vw2r/dialysis_products) has announced the addition of the "Dialysis Products and Services Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020" report to their offering. According to the National Institutes of Health, the worldwide number of patients with chronic kidney disease is rising rapidly and is expected to rise by approximately 5% to 8% annually. Increasing prevalence of diabetes and hypertension are the two primary causes of end stage renal disease in major developing countries like China, Brazil and India and is also contributing to the growth of overall dialysis products and services market. According to the American Kidney Fund, diabetes and hypertension are responsible for 38.4% and 25% of all cases of kidney failures, respectively. Similarly, increasing geriatric population and low preference by patients above 65 years of age to opt for kidney transplant is also driving the growth of dialysis products and services market. According to the Australian Institute of Health and Welfare, the proportion of people opting for kidney transplantation decreases with age. Moreover, increasing awareness about peritoneal dialysis is expected to boost the growth of the market in the near future. The global dialysis products and services market is segmented by type of procedures and type of services. The procedures market is further segmented into hemodialysis and peritoneal dialysis. Further, the hemodialysis segment (HD) is classified into HD machine, dialyzer, access products/catheters, bloodlines, concentrates and others, which include water treatment systems and fistula needles. Hemodialysis, being the oldest and most preferred technique for dialysis procedure, Hemodialysis machines captures the largest share, of the total market in 2013. The segment is expected to lead the market during the forecast period from 2014 to 2020. Similarly, peritoneal dialysis (PD) segment is classified into concentrates/dialysate, PD machines, catheters, and transfer sets. Among these, the PD concentrates/dialysate segment is accounted for largest market share in 2013 and is expected to grow at an attractive higher growth rate during the forecast period from 2014 to 2020. The major factors responsible for the significant growth of this segment are increase in the number of patients preferring peritoneal dialysis, and rising demand of patients to be dialyzed overnight with the aid of peritoneal dialysis. Dialysis Products and Services Market, by Product type: Hemodialysis - HD Machines - Dialyzers - HD Access Products/Catheters - Bloodlines - HD Concentrates/Dialysate - Others (Water Treatment System, Fistula Needles) Peritoneal Dialysis - Concentrates/Dialysate - PD Machines - PD Catheters - PD Transfer Sets Dialysis Products and Services Market, by Type of Services: - In-center Dialysis - Home Dialysis Companies Mentioned - Asahi Kasei Corporation - B. Braun Melsungen AG - Baxter International, Inc. - C. R. Bard, Inc. - Cantel Medical Corporation - Covidien plc - DaVita Healthcare Partners, Inc. - Fresenius SE & Co. KGaA - Kawasumi Laboratories, Inc. - Medical Components, Inc. - Nikkiso Co., Ltd. - Nipro Corporation - NxStage Medical, Inc. - Rockwell Medical Technologies, Inc. For more information visit http://www.researchandmarkets.com/research/c8...s_products
NXTM: 16.46 (+1.26), BAX: 71.60 (+0.70), RMTI: 9.33 (+0.15), CMN: 41.50 (+0.02)
NxStage Patients Participate in 257-Mile Tour DaVita Bike Ride
PR Newswire - Wed Sep 10, 7:00AM CDT
NxStage Medical, Inc. (NASDAQ: NXTM), a leading manufacturer of innovative dialysis products, is proud to support four kidney failure patients performing home hemodialysis (HHD) treatment with the NxStage® System One(TM) as they ride in the eighth annual Tour DaVita®. Beginning on September 14 in Oregon, each patient will bike up to 257 miles over the course of three days, raising awareness for kidney disease and dialysis treatment options, including HHD. Thanks to the portability and flexibility of treatment schedules with the NxStage System One, all four patients will dialyze in a recreational vehicle along the route with the support of a care partner.
NXTM: 16.46 (+1.26)
NxStage Kidney Care Opens New Orlando Florida Dialysis Center
PR Newswire - Wed Aug 20, 9:00AM CDT
NxStage Kidney Care, Inc., a subsidiary of NxStage Medical, Inc. (Nasdaq: NXTM), today announced the opening of a new dialysis center serving the south Orlando area. NxStage Kidney Care's staff of highly trained nurses and medical professionals are committed to providing enhanced access to the significant clinical and quality of life benefits made possible through home therapy as well as flexible in-center options at the frequency and duration that works best for the patient.
NXTM: 16.46 (+1.26)
NxStage Medical appoints Dr. Allan J. Collins as senior medical advisor
M2 - Tue Aug 12, 7:27AM CDT
Medical dialysis company NxStage Medical (Nasdaq GS:NXTM) disclosed on Tuesday that Allan J Collins MD, has been elected as its senior medical advisor and head of its medical advisory board.
NXTM: 16.46 (+1.26)
Allan J. Collins, M.D., to join NxStage as Senior Medical Advisor
PR Newswire - Tue Aug 12, 7:00AM CDT
NxStage Medical, Inc. (NASDAQ: NXTM), a leading manufacturer of innovative dialysis products, announced today that Allan J. Collins, M.D., a recognized worldwide leader in the field of nephrology, will join the Company as Senior Medical Advisor and head the Company's Medical Advisory Board.
NXTM: 16.46 (+1.26)
NxStage Reports Record Second Quarter 2014 Financial Results And Increases Full-Year Revenue Guidance
PR Newswire - Thu Aug 07, 6:38AM CDT
NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today reported second quarter revenue that exceeds the top end of its guidance range.
NXTM: 16.46 (+1.26)
NxStage to Present at the 34th Annual Canaccord Genuity Growth Conference
PR Newswire - Fri Aug 01, 7:00AM CDT
NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced that Jeffrey H. Burbank, Chief Executive Officer, and Mathew Towse, Chief Financial Officer, will present at the 34th Annual Canaccord Genuity Growth Conference being held at the InterContinental in Boston, MA, on Wednesday, August 13th at 4:30 p.m. ET. A webcast of the event will be made available at http://ir.nxstage.com/.
NXTM: 16.46 (+1.26)
NxStage® to Report Second Quarter 2014 Financial Results
PR Newswire - Thu Jul 17, 7:01AM CDT
NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced plans to release its financial results for the second quarter ended June 30, 2014, on Thursday, August 7, 2014, before the opening of the financial markets.
NXTM: 16.46 (+1.26)
NxStage Drives to Educate Kidney Patients
PR Newswire - Wed Jul 16, 9:09AM CDT
NxStage® Medical, Inc. (NASDAQ: NXTM), a leading manufacturer of innovative dialysis products, announced today the launch of the NxStage Freedom Tour, a two week road trip in a recreational vehicle to promote and educate dialysis patients on the benefits of home hemodialysis with the NxStage System One(TM). Traveling in the NxStage Freedom Coach are NxStage field marketing specialists Charissa Rice and Harvey Wells. During the nine city tour, the duo will make stops outside of dialysis centers in Maryland, Pennsylvania, Connecticut, Massachusetts, New Jersey, New York, Virginia and North Carolina. Patients and care partners are invited inside the NxStage Freedom coach to watch Rice, who is also a NxStage user, perform her treatments with her care partner, learn about home hemodialysis and hear first-hand how the therapy has helped both Rice and Wells to reclaim their lives.
NXTM: 16.46 (+1.26)
Mariel Therapeutics Acquires Stryker Assets - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jul 08, 5:35PM CDT
Stryker Corporation's (SYK) BMP-7 assets will be used by Mariel for the potential treatment of osteoarthritis, chronic kidney disease and other organ fibrosis conditions.
NXTM: 16.46 (+1.26), CSII: 29.87 (-0.01), OSUR: 9.01 (+0.32), SYK: 88.55 (+0.53)
(0)
(0)NxStage Medical Inc. (NXTM) Stock Research Links
Scroll down for more posts ▼